{"entity":"abbvie","id":"ent_abbvie","name":"AbbVie","wikidata":"Q14662364","page":"https://asof.is/record/abbvie","summary":"AbbVie is a pharmaceutical company, headquartered in North Chicago. Its CEO is Robert A. Michael, since 2024. It reported revenue of $56.33B for the period ended December 31, 2024.","title":"AbbVie: CEO Robert A. Michael, revenue $56.33B","key_facts":[{"label":"CEO","value":"Robert A. Michael","note":"since 2024","claim":"clm_5B7824F67B5A"},{"label":"CFO","value":"Scott T. Reents","claim":"clm_5E1BA5E19048"},{"label":"Headquarters","value":"North Chicago","claim":"clm_E74DBC8CCF1E"},{"label":"Revenue","value":"$56.33B","recorded":"56,334,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_46C087CADCC6"},{"label":"Ticker","value":"ABBV · NYSE","claim":"clm_B87EDEAECF6B"}],"faq":[{"question":"Who is the CEO of AbbVie?","answer":"Robert A. Michael, since 2024, as the AsOf record states with its sources."},{"question":"Where is AbbVie headquartered?","answer":"North Chicago."},{"question":"What is AbbVie's revenue?","answer":"$56.33B for the period ended December 31, 2024."}],"as_of":"2025-11-08","known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/abbvie/ceo","md":"https://asof.is/record/abbvie/ceo.md","json":"https://asof.is/v1/entities/abbvie/ceo"},{"predicate":"cfo","page":"https://asof.is/record/abbvie/cfo","md":"https://asof.is/record/abbvie/cfo.md","json":"https://asof.is/v1/entities/abbvie/cfo"},{"predicate":"headquarters","page":"https://asof.is/record/abbvie/headquarters","md":"https://asof.is/record/abbvie/headquarters.md","json":"https://asof.is/v1/entities/abbvie/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/abbvie/revenue","md":"https://asof.is/record/abbvie/revenue.md","json":"https://asof.is/v1/entities/abbvie/revenue"},{"predicate":"net_income","page":"https://asof.is/record/abbvie/net_income","md":"https://asof.is/record/abbvie/net_income.md","json":"https://asof.is/v1/entities/abbvie/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/abbvie/operating_income","md":"https://asof.is/record/abbvie/operating_income.md","json":"https://asof.is/v1/entities/abbvie/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/abbvie/quarterly_revenue","md":"https://asof.is/record/abbvie/quarterly_revenue.md","json":"https://asof.is/v1/entities/abbvie/quarterly_revenue"}],"products":[],"coverage":{"entity":"abbvie","name":"AbbVie","kind":"organization","sources":[{"source":"wikidata","item":"Q14662364","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":1551152,"ticker":"ABBV","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":402,"open":18,"retracted":0,"first":"2010-12-31","predicates":{"total_equity":{"claims":56,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":34,"open":1,"kind":"fact"},"total_assets":{"claims":56,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":45,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":61,"open":1,"kind":"fact"},"shares_outstanding":{"claims":55,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":45,"open":1,"kind":"fact"},"net_income":{"claims":12,"open":1,"kind":"fact"},"revenue":{"claims":15,"open":1,"kind":"fact"},"operating_income":{"claims":15,"open":1,"kind":"fact"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":402,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_E498EA77B417","predicate":"cash_and_equivalents","value":"5,629,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,629,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_E498EA77B417, https://asof.is/claim/clm_E498EA77B417, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_E498EA77B417","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F526599F9FFE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_5B7824F67B5A","predicate":"ceo","value":"Robert A. Michael","valid_from":"2024-07-01","valid_to":null,"published":"2026-03-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie ceo: Robert A. Michael\", as of 2024-07-01. Claim clm_5B7824F67B5A, https://asof.is/claim/clm_5B7824F67B5A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm.","url":"https://asof.is/claim/clm_5B7824F67B5A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q14662364","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-23T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/tm246649d1_ex99-1.htm","tier":"primary","publisher":null,"published_at":null}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer - Richard A. Gonzalez to retire as AbbVie CEO to become executive chairman - Transition will occur on July 1, 2024","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/tm246649d1_ex99-1.htm"}},{"id":"clm_5E1BA5E19048","predicate":"cfo","value":"Scott T. Reents","valid_from":null,"undated":true,"valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cfo: Scott T. Reents\", undated. Claim clm_5E1BA5E19048, https://asof.is/claim/clm_5E1BA5E19048, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm.","url":"https://asof.is/claim/clm_5E1BA5E19048","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm","tier":"primary","publisher":"SEC EDGAR 10-K","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Scott T. Reents 58 Executive Vice President, Chief Financial Officer","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm"}},{"id":"clm_CD48BB22552C","predicate":"cik","value":"0001551152","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cik: 0001551152\", undated. Claim clm_CD48BB22552C, https://asof.is/claim/clm_CD48BB22552C, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_CD48BB22552C","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_D5837D9B7367","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie fiscal year end: 12-31\", undated. Claim clm_D5837D9B7367, https://asof.is/claim/clm_D5837D9B7367, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_D5837D9B7367","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_E74DBC8CCF1E","predicate":"headquarters","value":"North Chicago","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie headquarters: North Chicago\", undated. Claim clm_E74DBC8CCF1E, https://asof.is/claim/clm_E74DBC8CCF1E, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_E74DBC8CCF1E","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_BBC331549951","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie listed on: NYSE\", undated. Claim clm_BBC331549951, https://asof.is/claim/clm_BBC331549951, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_BBC331549951","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4595D4B200E2","predicate":"net_income","value":"4,278,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,278,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_4595D4B200E2, https://asof.is/claim/clm_4595D4B200E2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_4595D4B200E2","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A3E6A20A337","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_7198B453007F","predicate":"operating_income","value":"9,137,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 9,137,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_7198B453007F, https://asof.is/claim/clm_7198B453007F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_7198B453007F","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D4AF640165D7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_48C26099DBC0","predicate":"quarterly_net_income","value":"186,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 186,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_48C26099DBC0, https://asof.is/claim/clm_48C26099DBC0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_48C26099DBC0","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_879DEDC1ACEA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_8A7602897846","predicate":"quarterly_operating_income","value":"1,904,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,904,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8A7602897846, https://asof.is/claim/clm_8A7602897846, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_8A7602897846","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78F42A193166","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_7673BF825A9D","predicate":"quarterly_revenue","value":"15,776,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 15,776,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_7673BF825A9D, https://asof.is/claim/clm_7673BF825A9D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_7673BF825A9D","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A1D46B6132E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_78F47A4D8706","predicate":"registrant_name","value":"AbbVie Inc.","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie registrant name: AbbVie Inc.\", undated. Claim clm_78F47A4D8706, https://asof.is/claim/clm_78F47A4D8706, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_78F47A4D8706","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_46C087CADCC6","predicate":"revenue","value":"56,334,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 56,334,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_46C087CADCC6, https://asof.is/claim/clm_46C087CADCC6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_46C087CADCC6","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4A7BE8ED0078","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_A66CE3EA88E8","predicate":"shares_outstanding","value":"1,767,384,632 shares","valid_from":"2025-10-27","valid_to":"2026-02-10","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,384,632 shares\", as of 2025-10-27 (until 2026-02-10). Claim clm_A66CE3EA88E8, https://asof.is/claim/clm_A66CE3EA88E8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_A66CE3EA88E8","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F33386E6A71F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_60D3FAD20B06","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_60D3FAD20B06, https://asof.is/claim/clm_60D3FAD20B06, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_60D3FAD20B06","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_50468CC9D02A","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie state of incorporation: DE\", undated. Claim clm_50468CC9D02A, https://asof.is/claim/clm_50468CC9D02A, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_50468CC9D02A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B87EDEAECF6B","predicate":"ticker","value":"ABBV","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie ticker: ABBV\", undated. Claim clm_B87EDEAECF6B, https://asof.is/claim/clm_B87EDEAECF6B, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_B87EDEAECF6B","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_9AD5C074902A","predicate":"total_assets","value":"133,898,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 133,898,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_9AD5C074902A, https://asof.is/claim/clm_9AD5C074902A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_9AD5C074902A","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BAF68C4E73F9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_E6BEEAB8A7CC","predicate":"total_equity","value":"-2,642,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -2,642,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_E6BEEAB8A7CC, https://asof.is/claim/clm_E6BEEAB8A7CC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_E6BEEAB8A7CC","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6A970AB08DB3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date"}}}